NCT01656642View on ClinicalTrials.gov

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 13, 2012

Primary Completion Date

March 25, 2020

Study Completion Date

March 25, 2020

Conditions
Malignant Melanoma
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered q3w or q2w.

DRUG

Cobimetinib

Oral repeating dose

DRUG

Vemurafenib

Oral repeating dose, depending on arm/cohort

Trial Locations (8)

34232

Florida Cancer Specialists - Sarasota, Sarasota

37203

Sarah Cannon Research Institute, Nashville

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Health Science Center; Biomedical Research Bldg. Room 511, Aurora

90024

UCLA, Los Angeles

90025

The Angeles Clinic and Research Institute - W LA Office, Los Angeles

02114

Massachusetts General Hospital., Boston

02215

Dana Farber Can Ins, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01656642 - A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | Biotech Hunter | Biotech Hunter